HeartBeam Future Growth

Future criteria checks 2/6

HeartBeam is forecast to grow earnings and revenue by 48.4% and 77.2% per annum respectively while EPS is expected to grow by 23% per annum.

Key information

48.4%

Earnings growth rate

23.0%

EPS growth rate

Medical Equipment earnings growth	13.0%
Revenue growth rate	77.2%
Future return on equity	n/a
Analyst coverage	Low
Last updated	19 Dec 2024

Recent future growth updates

Recent updates

HeartBeam gets patent to enable generation of its credit card-sized ECG, shares rise ~15%

Sep 28

HeartBeam surges 54% on U.S. patent for ECG patch monitor to detect heart attacks

Sep 15

HeartBeam GAAP EPS of $0.43 beats by $0.70

Aug 11

HeartBeam: Cardiovascular Diagnostics On The Go

Dec 14

Earnings and Revenue Growth Forecasts

NasdaqCM:BEAT - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2027	13	N/A	N/A	N/A	1
12/31/2026	4	N/A	N/A	N/A	1
12/31/2025	6	-10	N/A	N/A	2
12/31/2024	N/A	-19	N/A	N/A	2
9/30/2024	N/A	-18	-13	-13	N/A
6/30/2024	N/A	-17	-12	-12	N/A
3/31/2024	N/A	-15	-13	-12	N/A
12/31/2023	N/A	-15	-12	-12	N/A
9/30/2023	N/A	-14	-12	-12	N/A
6/30/2023	N/A	-15	-13	-13	N/A
3/31/2023	N/A	-15	-11	-11	N/A
12/31/2022	N/A	-13	-10	-10	N/A
9/30/2022	N/A	-11	-9	-9	N/A
6/30/2022	N/A	-9	-7	-7	N/A
3/31/2022	N/A	-6	-5	-5	N/A
12/31/2021	N/A	-4	-3	-3	N/A
9/30/2021	N/A	-3	-1	-1	N/A
6/30/2021	N/A	-2	-1	-1	N/A
3/31/2021	N/A	-1	-1	-1	N/A
12/31/2020	N/A	-1	-1	-1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BEAT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BEAT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BEAT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BEAT's revenue (77.2% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: BEAT's revenue (77.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BEAT's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/31 00:21
End of Day Share Price	2025/01/31 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

HeartBeam, Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Benjamin Haynor	Alliance Global Partners
William Sutherland	Benchmark Company
Leo Carpio	Joseph Gunnar & Co., LLC

HeartBeam Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target decreased by 38% to US$5.00

Price target decreased by 38% to US$5.00

No longer forecast to breakeven

Recent updates

HeartBeam Achieves Major Milestone with FDA Submission for its Groundbreaking 12-Lead ECG Synthesis Software

HeartBeam, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

HeartBeam, Inc. Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology

Heartbeam, Inc. Announces Positive Data from Two Studies At Prestigious American Heart Association Conference

New minor risk - Share price stability

HeartBeam, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Heartbeam Announces Chief Executive Officer Changes, Effective October 21, 2024

Here's Why We're Watching HeartBeam's (NASDAQ:BEAT) Cash Burn Situation

HeartBeam, Inc. Appoints Timothy Cruickshank as Chief Financial Officer

New major risk - Financial position

HeartBeam, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Price target decreased by 38% to US$5.00

HeartBeam, Inc. has filed a Follow-on Equity Offering in the amount of $17 million.

HeartBeam, Inc., Annual General Meeting, Jun 12, 2024

HeartBeam, Inc. to Report Q1, 2024 Results on May 09, 2024

Price target decreased by 38% to US$5.00

High number of new and inexperienced directors

HeartBeam, Inc. Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias

New major risk - Revenue and earnings growth

High number of new and inexperienced directors

HeartBeam, Inc. Announces First Patients Enrolled in Pivotal Study Evaluating HeartBeam's AIMIGo System for Synthesizing A 12-Lead ECG

HeartBeam, Inc. Receives Two New US Patents for Its Core Cardiac Monitoring Technology

HeartBeam, Inc. to Report Q4, 2023 Results on Mar 20, 2024

HeartBeam, Inc. Announces Retirement of Richard Brounstein as Chief Financial Officer

HeartBeam, Inc. Unveils AI Program Designed to Deliver Unprecedented Personalized Cardiac Insights

HeartBeam, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Heartbeam, Inc. Appoints Richa Gujarati as Senior Vice President, Product

HeartBeam, Inc. Appoints Michael R. Jaff to the Board of Directors

Less than half of directors are independent

Heartbeam Appoints Ken Nelson and Mark Strome to the Board of Directors

HeartBeam, Inc., Annual General Meeting, Jul 07, 2023

HeartBeam, Inc. Announces Automated Cardiac Detection Patent Granted for Heartbeam Aimigo™ System

HeartBeam, Inc. to Report Q1, 2023 Results on May 11, 2023

No longer forecast to breakeven

HeartBeam, Inc. Appoints Robert Eno as President

Companies Like HeartBeam (NASDAQ:BEAT) Could Be Quite Risky

HeartBeam Receives European Patent for Signal Transformation from Vector Electrocardiogram (VECG) to 12-Lead Electrocardiogram (ECG)

HeartBeam, Inc. Announces Patent for 12-Lead Electrocardiogram Smartwatch-Based Monitor

Less than half of directors are independent

HeartBeam, Inc. to Report Q3, 2022 Results on Nov 10, 2022

HeartBeam Names Peter J. Fitzgerald, MD, PhD, as Chief Medical Officer

HeartBeam gets a new chief medical officer

HeartBeam Broadens Product Portfolio Pipeline with Smartwatch Connectivity Enablement for 24/7 Heart Monitoring Solution

Heartbeam Grants Patent for Signal Transformation from Vector Electrocardiogram (VECG) to 12-Lead Electrocardiogram (ECG)

HeartBeam gets patent to enable generation of its credit card-sized ECG, shares rise ~15%

HeartBeam surges 54% on U.S. patent for ECG patch monitor to detect heart attacks

Heartbeam Announces FDA Submission of Heartbeam Aimi™ Product

Heartbeam, Inc. Announces Resignation of Alan Baumel as Chief Operating Officer, Effective on August 15, 2022

HeartBeam GAAP EPS of $0.43 beats by $0.70

HeartBeam, Inc. Announces the Appointment of Ken Persen to the Role of Chief Technology Officer

HeartBeam, Inc. to Report Q2, 2022 Results on Aug 11, 2022

HeartBeam, Inc., Annual General Meeting, Jun 15, 2022

No independent directors

HeartBeam, Inc. Announces Board Changes

HeartBeam: Cardiovascular Diagnostics On The Go

Director exercised options to buy US$1.4m worth of stock.

No independent directors

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources